Month: May 2021

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trialAdjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups High immune response after a single dose in patients with prior infection shows strong booster potential Global Phase 3 study expected to start in the coming weeksPARIS and LONDON – May 17, 2021 – The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks. The Phase 2 interim results showed 95% to 100% seroconversion following...

Wereldhave and The Sting Companies are strengthening their collaboration by extending three lease agreements in Tilburg totaling more than 17,000 m². This demonstrates the confidence retailers have in Tilburg as shopping destination as well as the quality of one of Wereldhave’s largest committed Full Service Center transformations. The temporary agreement with concept store De KOOPman in the former Hudson’s Bay building has been changed in a long-term permanent lease for the full building. De KOOPman in Tilburg opened its doors in May 2020 in the former Hudson’s Bay building, with a total surface area of approximately 13,170 m². Even during the pandemic, the new formula proved to be a great success. As part of the agreement, the KOOPman will eventually be converted to a new concept from The Sting Companies. Additionally, the...

Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain on the Board as a Non-executive Director of the company. Mr. Graney has extensive capital markets and business development experience in biotech as...

KEY DATA For Q1 2021 we record the following key data:The EPRA earnings end of March 2021 amount to € 7.2 million, in line with end of March 2020 (€ 7.3 million) The occupancy rate rises from 91.62% (31/12/2020) to 92.05% The funding cost drops to 2.23% (2020: 2.35%) The debt ratio decreases from 55.58% end 2020 to 54.56% Proposal for approval of the dividend distribution over the financial year 2020 of € 5.25 gross per share (same dividend distribution as over the financial year 2019), approval of which will be submitted to the general meeting of today, held at 16.00h.Attachment2021 05 17_LRE Q1 2021 and OGM_ENG_Final

EL DORADO, Ark., May 17, 2021 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), an innovative technology and lithium project development company has commenced work on a Preliminary Economic Assessment (“PEA”) on its TETRA Property located in the south-western region of Arkansas. The PEA will consider an integrated project including; brine supply and injection wells, pipelines and brine treatment infrastructure, a Direct Lithium Extraction plant using the Company’s proprietary LiSTR technology, and a lithium chloride to lithium hydroxide conversion plant. Standard Lithium has engaged NORAM Engineering and Constructors Ltd. (“NORAM”) as the lead consultant, to prepare and coordinate the PEA with support of a multi-disciplinary team. NORAM will be supported by Hunt,...

Lochem, 17 May 2021 Update share buy-back programme ForFarmers ForFarmers N.V. (ForFarmers) has repurchased 55,055 shares in the period from 10 May 2021 through 14 May 2021. The shares were repurchased at an average price of €5.38 per share, for a total amount of €296,378. These repurchases were made in accordance with the authorisation granted by the ForFarmers Annual General Meeting of Shareholders on 23 April 2021 to buy back shares. This decision was published the same day, and it was announced that the share buy-back programme would start on 28 April 2021. The total number of shares that has been repurchased to date according to this programme is 156,069 shares, for a total amount of €848,062. More information about the share buy-back programme is available on the ForFarmers website www.forfarmersgroup.eu/en. This press release...

Data published in Neuropharmacology supports therapeutic role of dipraglurant in this important movement disorder Geneva, Switzerland, May 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that dipraglurant was able to rescue long-term impairment of synaptic plasticity in two well validated models of dystonia. The data were published in the journal, Neuropharmacology, under the title “Rescue of striatal long-term depression by chronic mGlu5 receptor negative allosteric modulation in distinct dystonia models”, by a team led by Antonio Pisani, MD, PhD, from the Department of Brain and Behavioral Sciences, University of Pavia, and Mondino Foundation, Pavia, Italy. “There is an urgent need to identify targets...